Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
- CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
- GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Tweets from GSK
-
GSK @GSK
Thanks to all our employees, around the world, who have raised £4 million for our partnership with @savechildrenuk. Together we’ve helped nearly 3 million children in 46 countries. Learn more: gsk.to/2LDdSkZ 👇#globalhealthhd
about 20 hours ago -
GSK @GSK
We’re pleased to see the earlier science undertaken at the GSK Vaccines Institute for Global Health leading to a new vaccine for typhoid, delivered by Biological E. Learn more: gsk.to/3bOh0nc
about 21 hours ago
-
GSK @GSK
We’re delighted that Biological E in collaboration with the GSK Vaccines Institute for Global Health have delivered a new vaccine in the fight against typhoid. We’re proud to work with leading organisations to make an impact in global health. Learn more: gsk.to/3bOh0nc
about 1 day ago
